UPCOMING SESSIONS in ET
Wed, May 13, 2026
10:00 – 11:00 PM UTC
Amyloidosis Patient Profile: How I Changed My Life for the Better After Receiving an Amyloidosis Diagnosis Alison Keenan Click To Register
UPCOMING SESSIONS in ET
Wed, May 13, 2026 · 10:00 – 11:00 PM UTC
Amyloidosis Patient Profile: How I Changed My Life for the Better After Receiving an Amyloidosis Diagnosis
Alison Keenan
Click To Register
View all sessions

Clinical Trials and Research

The Pharma Letter
May 11, 2026
First look at Wainua in ATTR-CM Phase III CARDIO-TTRansform data
This weekend at the European Society of Cardiology’s Heart Failure 2026 Congress in Barcelona), the first data from AstraZeneca’s (LSE: AZN) Phase III CARDIO-…
Read more
amyloidosis
May 06, 2026
Wainua slows disease progression for adults with hATTR-PN, per trial analysis
Use of the approved therapy Wainua (eplontersen) effectively slows disease progression and improves quality of life among adults with hereditary transthyretin…
Read more
Oxford Academic
May 06, 2026
CARDIAC AMYLOIDOSIS IN OLDER ADULTS AGED ≥80 YEARS: REAL–WORLD CLINICAL AND BIOMARKER STABILITY WITH TAFAMIDIS
AbstractBackgroundTransthyretin cardiac amyloidosis (ATTR–CM) is an increasingly recognised cause of heart failure in older adults, but real–world data in patients…
Read more
American Heart Association Journals
May 06, 2026
Three‐Dimensional Visualization and Proteomic Analysis of Human Cardiac Transthyretin Amyloidosis Tissue Reveals Microangiopathy and Capillary Occlusion
AbstractBackgroundTransthyretin amyloidosis (ATTR) is a degenerative disease affecting the heart and other organs. Transthyretin (TTR) aggregation is a driver of…
Read more
Nature
May 04, 2026
Fibroblast growth factor 23 is associated with cardiac disease severity in transthyretin amyloid cardiomyopathy
Fibroblast growth factor 23 (FGF23), a bone-derived hormone, is emerging as a potential biomarker in cardiovascular disease. However, its role in transthyretin…
Read more
AFP
May 04, 2026
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
CAMBRIDGE, Mass.Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for…
Read more
Rare Disease Advisor
May 01, 2026
Novel Radiotracer Could Help Diagnose ATTR-CM and Rare Forms of Amyloidosis
I-evuzamitide positron emission tomography/computed tomography (PET/CT) can help diagnose heart involvement in rare forms of amyloidosis as well as transthyretin-…
Read more
Subscribe to